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Abstract
Cold atmospheric plasma (CAP) is a specific type of partially ionized gas that is less than
104˚F at the point of application. It was recently shown that CAP can be used for decontam-
ination and sterilization, as well as anti-cancer treatment. Here, we investigated the effects
of CAP on HIV-1 replication in monocyte-derived macrophages (MDM). We demonstrate
that pre-treatment of MDM with CAP reduced levels of CD4 and CCR5, inhibiting virus-cell
fusion, viral reverse transcription and integration. In addition, CAP pre-treatment affected
cellular factors required for post-entry events, as replication of VSV-G-pseudotyped HIV-1,
which by-passes HIV receptor-mediated fusion at the plasma membrane during entry, was
also inhibited. Interestingly, virus particles produced by CAP-treated cells had reduced
infectivity, suggesting that the inhibitory effect of CAP extended to the second cycle of
infection. These results demonstrate that anti-HIV activity of CAP involves the effects on
target cells and the virus, and suggest that CAP may be considered for potential application
as an anti-HIV treatment.
Introduction
Cold atmospheric plasma (CAP) is a specific form of ionized gas defined as non-thermal non-
equilibriumplasma, i.e. a quazi-neutral gas with fast electrons and relatively slow ions. CAP
has a complex chemical composition and some of the charged particles detected in the CAP,
such as NO-, NO2-, OH-, O-, as well as reactive oxygen species (O3, O), have important biologi-
cal and biomedical activities. The ongoing research suggests that CAP can be used for decon-
tamination and sterilization, and appears to be quite effective in virus inactivation [1–4]. The
mechanisms behind the anti-viral activity of CAP are poorly understood, but may include both
a direct effect on viral particles via bioactive ions and indirect suppression via modification of
cell surface receptors important for viral replication [5].
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In this study, we investigated the CAP effects on replication of HIV-1. Natural targets of HIV-1
are myeloid cells and CD4-positive T lymphocytes. Since we used plasma jet to produce CAP, we
performed this study on adherent monolayers of monocyte-derivedmacrophages to eliminate var-
iability associatedwith treatment of suspension cultures of CD4+ T cells. Indeed, careful quantifi-
cation of the CAP effects in suspension cultures would be difficult due to a multilayer composition
of such cultures, which shields lower level cells from irradiation.Here, we report for the first time
that CAP treatment induces a suppression of the HIV-1 replication in macrophages by reducing
virus-cell fusion and infectivity of the virus produced by treated cells. These data can be further
exploited to develop therapies using CAP in combination with other existing approaches.
Materials and Methods
Biosafety
All experiments with live HIV-1 were performed under the BSL-2 conditions.
Cell lines, primary cells, HIV constructs, and infection
Plasma from uninfected donors was obtained from a commercial source (New York Blood
Center, www.nybloodcenter.org), and donor identity and identifiable characteristics were
unknown to investigators. Therefore, per NIH definition, this research does not qualify as
research on human subjects. Primarymonocytes were isolated from plasma as described [6]
and plated in the 24-wells primary culture plates (1 x 106 cells per well). Cells were cultured for
~7 days in RPMI media with 10% of human serum supplemented with M-CSF (2 ng/ml). Cell
confluencewas ~ 40–60%.
Macrophage-tropic HIV-1 ADA [7] was obtained through the NIH AIDS Reagent Program
(Cat. # 416), propagated on primaryMDM and kept frozen at -70°C. To prepare VSV-G-pseu-
dotypedHIV-1 virions, human embryonic kidney (HEK) 293T/17 cell line [8, 9] was used. The
cell line was purchased from ATCC (Cat. # CRL-11268™) in 2005, aliquoted and stored frozen.
Cells were co-transfectedwith pNL4-3 [10] and pHEF-VSVG [11]. Culture supernatants col-
lected 96 h after transfection were filtered through a 0.22 μm filter. CAP-treated macrophages
were infected with HIV-1 ADA (R5 strain) or VSV-G-pseudotyped HIV-1 LAI (X4 strain) at 5
x 105 cpm of RT activity/1x106 cells for 3 hours, followed by 3 washes with 1 x PBS. Infected
cells were cultivated in fresh complete medium; every 3–4 days, half of the mediumwas
changed and checked for RT activity.
CAP treatment
The CAP jet is the dielectric barrier discharge device shown in Fig 1A. The working parameters
were: the output voltage was 4.5 kV in helium, the frequency~13 kHz, the gas flow rate ~10 L/
min. The distance between the jet outlet and culture plate was kept about 20 mm. The average jet
dose at this distance was ~ 0.8 J/sec x cm2. The CAP beamdiameter was about 8 mm, and intensity
distributionwithin the beam at the well surface is shown in Fig 1B. The helium beamwas used as a
control for all experiments.We checked the surface temperature during irradiation using non-cou-
pled infrared thermocouple, as described in our previous reports [12, 13]. The temperature was
maintained at 37°C, and no temperature increases were observedduring or after CAP treatment.
Cell culture mediumwas changed right after CAP treatment to avoid medium effects on cells.
MTT Assay
Cells were incubated with 7 mg/ml of Thiazolyl Blue Tetrazolium Bromide for 4 hours at
37°C. After removal of the supernatant and washing with PBS, acidic isopropanol solution
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(absolute isopropanol with 0.1 N HCl) was added. The results were read at 570 nm on an
ELISA reader.
Reverse Transcriptase Assay
10 μL of the medium from infected cultures was mixed with 10 μL of 5 x RT buffer (250 mM
Tris-HCl, pH 8.0, 5 mMDTT, 25 mMMgCl2, 100 mMKCl), 10 μL of poly-A (1 U/mL), 10 μL
of poly-dT (1 U/mL), 2 μL of [3H]TTP (40 μCi/mL), 3 μl H2O and 5 μL Triton 1%. Following
incubation for 2 h at 37°C, 5 μL of the mixture was spotted on DEAE Filtermat paper, dried,
washed in 5% Na2HPO4, and rinsed 3 times in H2O and 1 time in 70% EtOH. Samples were
dried again, sealed in the sample bags, and counted on a Betaplate counter.
Fig 1. Characteristics of the CAP device. A. Experimental setup of CAP treatment. Reactive oxygen and nitrogen species in the plasma stream are
shown. B. CAP intensity distribution in the jet beam at the well surface. C. Optical emission spectrum at the jet’s end characterizes irradiation from the
entire length of the plasma column (CAP).
doi:10.1371/journal.pone.0165322.g001
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Live Cell Staining
Macrophage cultures were washed on ice with 1 x PBS followed by addition of 10 mM EDTA
for 5–10 min at room temperature. Cells were aspirated into the microfuge tubes, washed with
1 x PBS twice, and resuspended in blocking buffer for Human Fc receptor (Bioscience) for 30–
60 min on ice. After incubation with Fc block, without washing, antibodies were added for 30
min on ice. Cells were then washed, resuspended in 2% FBS and stained. Fixable Viability Dye
eFluor1450 (Bioscience), a viability dye, was used at a 1:1,000 dilution to irreversibly label
dead cells. CCR5 was stained using anti-human CD195 (BD Pharmigen), CD4 –using anti-
human Leu-3 T4 (Bioscience), with isotype controls mouse IgG2a K (BD Pharmigen) and
mouse IgG2b K (Bioscience), respectively.
Flow cytometry
Flow cytometry analyses were performed on a FACSCalibur DxP8 at the GWU Flow Cytome-
try Core Facility. The analyzer is equipped with three lasers (providing excitation wavelengths
of 488, 637 and 407 nm) and eight detectors for fluorescence.
Data Analysis
Statistical analysis of data was performed by means of InStat 3 software (Graphpad Software).
The Kolmogorov-Smirnov test was applied to test for Gaussian distribution. Depending on the
sample size, parametric or non-parametric analysis was used to determine the means and stan-
dard deviation values. The differences between groups were determined by two tail unpaired t-
tests. Data were considered significant for p-values< 0.05.
Results and Discussion
CAP treatment was applied to cells using 3 shots (45 sec at 4.5 kV) per well in a 24-well plate. To
determine the percentage of cells affected by CAP treatment we measured the spectrumacross the
plasma jet flow. The special plastic holder for spectrometer probe was built and used for 1 mm step
measurements. The O2 (First Negative) peak at 327 nm (the highest intensity in the spectrum, see
Fig 1C) was chosen to evaluate the jet performance. The full width of the distribution (the jet beam
diameter) was found to be ~8mm. Thus, for the well diameter of 15.6 mm, 3 shots cover 80% of
the well area, indicating that 80% of cells are treated. Given that over 80% of intensity is localized to
the area with 4 mm diameter (new Fig 1B), about 25% of affected cells receivedmaximal treatment.
In total, 20% of cells on the plate receivedmaximal treatment, 60% got intermediate dose, and 20%
were not treated at all. The cold plasma jet system operated at atmospheric pressure can produce
chemically active species, particularly oxygen and nitrogen atoms [14, 15]. To characterize the
emission spectrumof our jet, we employed optical emission spectroscopy (OES) over a wide range
of wavelengths from 200 nm to 900 nmwith an optical emission spectroscope (SV 2100, K-MAC).
The dominant emission lines illustrate the presence of excited oxygen ions (O2+) at 300–350 nm
and atomic oxygen (O) at 800–844 nm (Fig 1C).We also detectedNO species in the 200–300 nm
range, and reactive nitrogen speciesN2 (N2 second positive system) and ionized nitrogenmolecules
N2+ (N2+ first negative system) in the ranges of 300–420 nm and 400–500 nm, respectively (Fig
1C). In addition,many other reactive species, such as OH, H2O2, ONOO- and others (shown sche-
matically in Fig 1A), are formed in the liquid phase in the cell culturemedium [15]. However,
despite abundance of these bioactivemolecules,CAP treatment was not cytotoxic to uninfected
macrophages, as evidencedby unchanged cell morphology (Fig 2A) and metabolic activitymea-
sured by MTT assay (Fig 2B). Previously, CAP treatment using the same conditions was shown to
be non-toxic to murine primary keratinocytes and epithelial cell lines [13].
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Analysis of HIV-1 replication in CAP-treated cells demonstrated a 3–4 fold reduction in RT
activity measured in culture supernatants over a period of 14 days (Fig 3A). This effect was
reproduced with MDM from 7 donors (Fig 3B). Such inhibitory effect could be due either to
the CAP effect on cells, which made them resistant to infection, or to the effect on the virus
produced in treated cells, which reduced its infectivity for the next round of infection.Of
course, it was possible that both these scenarios were at work.
To address the mechanism of CAP activity, we first analyzed HIV reverse transcription
products in cells treated with CAP prior to infection. This analysis demonstrated that both pos-
itive strand cDNA products of reverse transcription (Fig 3C) and integrated proviral DNA (Fig
3D) were reduced in CAP-treated cells by 2.5-fold and 3-fold, respectively. This result sug-
gested that viral entry or reverse transcription was defective in cells pre-treated with CAP.
We next tested whether treatment of the virus, rather than of the cells, with CAP reduced
infection. Results presented in Fig 3E demonstrate that treatment of the virus suspension with
CAP significantly reduced the ability of this virus to establish infection in MDM. These results
have been reproduced with MDM from 6 different donors. This effect of CAP could be due to
damage to the viral envelope, which prevented virus-cell fusion, or destruction of the viral cap-
sid leading to impairment of reverse transcription. Future studies would be needed to define
the exact mechanism involved in this activity of CAP.
Reduced efficiencyof reverse transcription and integration in cells treated with CAP could
be due to inhibited entry of the virus, impaired reverse transcription and integration, or both.
To investigate CAP effects on viral entry, we analyzed expression of HIV receptors on CAP-
treated macrophages. This analysis revealed that expression of both CD4 and CCR5 receptors
was reduced (Fig 4A1). Comparison of two experiments with MDM from different donors
demonstrated that this effect was reproducible and significant: CCR5 expression was reduced
by 70% and CD4 –by 30% (Fig 4A2). Reduced expression of HIV receptors was expected to
translate to reduced fusion betweenHIV-1 and target cell. We analyzed HIV-1-cell fusion
using the fluorescence resonance energy transfer-based fusion assay [16]. HEK 293T cells were
co-transfectedwith HIV-1 NL4-3 molecular clone and BlaM-Vpr, virions were collected by
Fig 2. Analysis of CAP cytotoxicity. A. Morphology of MDM after CAP treatment. Macrophages in the CAP-treated area were imaged 1 h and 24 h
after treatment (45 sec at 4.5 kV). B. Cell viability was assessed by MTT assay. MTT conversion to formazan was measured at OD570.
doi:10.1371/journal.pone.0165322.g002
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centrifugation and used to infect CAP-treated MDM loaded with CCF2-AM.Cells were ana-
lyzed by flow cytometry, using excitation at 409 nm and measuring emission at 520 nm
(uncleaved CCF2) and 450 nm (CCF2 cleaved by BlaM). Percentage of cells with cleaved CCF2
reflects the efficiencyof fusion.We found fusion to be reduced by about 40% (Fig 4B). This
result was reproduced with cells from a different donor. These results indicate that CAP treat-
ment modifies the cell membrane making them less susceptible to HIV infection. It should be
noted that the effectmeasured in the fusion assay (Fig 4B) represents the whole population of
treated cells, where 20% of cells remained untreated and 60% received sub-optimal dose (Fig
1B). Therefore, the actual inhibitory effect of CAP is likely more potent.
To determine whether changes in HIV receptors expression are the only reason for reduced
susceptibility of CAP-treated macrophages to HIV infection, we analyzed infection by VSV-G-
pseudotypedNL4-3 virus, which enters target cells via endocytosis thus bypassing the HIV
receptor-mediated fusion with the target cell plasma membrane during entry. This virus goes
through only one cycle of replication in macrophages. Surprisingly, replication of VSV-G-
pseudotypedHIV-1 was also significantly reduced in CAP-treated cells (Fig 4C). This result
suggests that, in addition to the effect on HIV receptors, CAP treatment affected cellular factors
involved in post-entry steps of HIV replication, e.g. nucleotides required for reverse transcrip-
tion. Given that CAP treatment was not associated with cytotoxicity, it appears that affected
Fig 3. CAP effects on HIV-1 replication. A. Monocyte-derived macrophages treated with CAP or helium (control) were infected with HIV-1 ADA and viral
replication was monitored for 15 days by RT activity in the culture supernatant. B. Results (mean±SD) are presented for RT analysis on day 15 after infection
(performed as in panel A) for 7 different donors. ****p<0.0001 by Student’s unpaired two-tail t-test. C. MDM infected with HIV-1 ADA as in A were analyzed
4 h post infection by qPCR for positive-strand cDNA. Cells treated with AZT (3 μM) and uninfected cells are shown as negative controls. Results are
presented as mean±SD for four independent infections with cells from one representative donor. ***p = 0.0004 by Student’s unpaired two-tail t-test. D. HIV-
infected MDM were analyzed 48 h post-infection by Alu-GAG qPCR for integrated proviral DNA. Results are presented as mean±SD for four independent
infections with cells from one representative donor. *p = 0.0494 by Student’s unpaired two-tail t-test. E. HIV-1 ADA was treated with CAP or helium (control)
and used to infect MDM. Virus infection was assessed by measuring reverse transcriptase activity in culture supernatant on day 10–15 post-infection.
Results (mean±SD) are presented for 6 experiments with MDM from independent donors. ***p<0.001 by Student’s unpaired two-tail t-test.
doi:10.1371/journal.pone.0165322.g003
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cellular factors are not essential for macrophage survival, at least during the period needed for
HIV infection to proceed through one cycle of replication in macrophages.
Next, using indicator TZM-bl cells, we analyzed infectivity of HIV virions collected from
CAP-treated macrophages. This analysis revealed a 4-fold reduction in infectivity of such virus
Fig 4. Mechanisms of anti-HIV activity of CAP treatment. A1. MDM treated with CAP or helium (control) were analyzed by flow cytometry for expression
of CCR5 and CD4. A2. Results are presented as mean ± SEM for analysis performed for MDM from two donors. P values (relative to control) were
calculated using Student’s unpaired two-tail t-test. B. Fusion between HIV-1 and MDM was analyzed by fluorescence resonance energy transfer-based
fusion assay. Cleavage of CCF2 represents virus-cell fusion. C. MDM treated with CAP or helium (control) were infected in triplicate wells with HIV-1 ADA
(R5 virus) or VSV-G-psudotyped HIV-1 NL4-3 (X4 virus), and viral production was measured on day 7 by RT activity. Results are presented as mean ± SD.
*p = 0.0037, **p = 0.027 relative to control, calculated using Student’s unpaired two-tail t-test. D. MDM treated with CAP or helium (control) were infected
with HIV-1 ADA and incubated for 21 days. Virus was collected, adjusted to the same RT activity by dilution, and used to infect indicator TZM-bl cells.
Results are presented as mean ± SD for 5 independent replicates. ****p<0.0001 by Student’s unpaired two-tail t-test.
doi:10.1371/journal.pone.0165322.g004
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relative to virus collected from control (helium-treated) cells (Fig 4D). This result suggests that
virus produced in CAP-treated cells is impaired during the next cycle of infection. Given that
cells were pre-treated with CAP, so CAP did not contact nascent virions, the observed
impairment is consistent with the observed inhibition of infection by VSV-G-pseudotyped
virus and was likely due to the effect on nascent virions of active radicals, reactive oxygen spe-
cies, and other bioactivemolecules produced in CAP-treated cells (Fig 1B).
Taken together, results of this study demonstrate that CAP-induced suppression of HIV
replication involves at least three major mechanisms: reduction of expression of HIV recep-
tors on target cells, which leads to reduced virus-cell fusion and virus entry, damage of cellu-
lar factors required for post-entry events of HIV replication and reduction of infectivity of
the produced virions, most likely via an indirect mechanismmediated by active radicals
formed as a result of CAP treatment, and direct damage of the virions by CAP. The contribu-
tion of each of these mechanisms may vary during the course of HIV spreading infection, e.g.
initially the fusion inhibition may dominate, whereas later the effect on virions may be the
major inhibitory mechanism. This interpretation is supported by a similarity between the
inhibitory effects of CAP on HIV replication at day 12 post-infection (about 4-fold, Fig 3A)
and infectivity of virions collected after 21 days of infection (4-fold, Fig 4D). Molecular
details of the mechanisms involved in these interesting activities of cold plasma await to be
determined.
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